EyeTherapy Blog News
Registration for Retina Day 2015 now open!
Wed, 10 Jun 2015 11:37:25 +0000
It’s that time once agin for our annual research day for patients and the public. Retina Day 2015 is a free, one day event is organised by the Gene and Cell Therapy Group, UCL Institute of Ophthalmology and NIHR Moorfields Biomedical Research Centre. Come along to: * Hear about some of the latest innovations in research […]Read more...
UCL Gene Therapy Trial shows Benefit for up to Three Years After Treatment
Tue, 05 May 2015 14:44:39 +0000
We are delighted to be able to announce that yesterday, Monday 4th May, the long-term results of our RPE65 gene therapy trial for Leber Congenital Amaurosis Type 2 (LCA2) were published in the prestigious New England Journal of Medicine. Begun in 2007, this was the world’s first-in-human trial of gene therapy to treat an inherited […]Read more...
UCL researchers solve a major riddle of retinal degeneration research!
Mon, 26 Jan 2015 10:11:36 +0000
Today a paper published in Nature Communications from the Gene and Cell Therapy Group at the UCL Institute of Ophthalmology has shed light on why, until now, it has not been possible to effectively restore vision in rd1 mice – the world’s major model for retinitis pigmentosa (RP). The rd1 mouse is a model of […]Read more...
A profile of Prof. Robin Ali by MRC insight
Professor Robin Ali is an MRC-funded scientist working at the forefront of not one, but two, fields of regenerative medicine: gene and stem cell therapy. Katherine Nightingale caught up with Robin at UCL’s Institute of Ophthalmology to find out more about his work.
Restoring vision in night blindness: Mice point way to stem cell therapy
Professor Robin Ali and his team at the UCL Institute of Ophthalmology have announced the first demonstration that transplanted retinal rod cells can improve vision in mice with night-blindness, publishing the results of their study in the prestigious science journal Nature.
Prof. Robin Ali named as Visionary of the Quarter by European Vision Institute
Gene therapy is a powerful new approach for the treatment of eye disease. We aim to develop gene therapy not only for a number of relatively rare, but currently untreatable, inherited retinopathies, but also to develop more effective treatments for common ocular disorders involving neovascularisation and inflammation.
Interview with Prof. James Bainbridge by the NIHR
James Bainbridge is a Wellcome Advanced Fellow and consultant surgeon. He has an established programme of translational research, developing new molecular treatments for retinal disorders. He is principal investigator for the first clinical trial of gene therapy for inherited eye disease. He is leader of the diabetes research theme for the NIHR Biomedical Research Centre.
Page last modified on 03 jan 13 10:55